Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: A systematic review

Diabetes, Metabolic Syndrome and Obesity

Volumn 5, Issue , 2012, Pages 165-174

  Berlie, Helen ^a   Hurren, Kathryn M ^a   Pinelli, Nicole R ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Exenatide; GLP 1; Liraglutide; Lixisenatide; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; AREA UNDER THE CURVE; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84866876811     PISSN: 11787007     EISSN: None     Source Type: Journal    
DOI: 10.2147/dmso.s27528     Document Type: Review

References (31)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303: 235-241.
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2011. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
3. Arbeeny CM. Addressing the unmet medical need for safe and effective weight loss therapies. Obes Res. 2004;12:1191-1196.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352: 854-865.
6. Inzucchi SE, Bergenstal RM, Buse JB., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. Epub April 19, 2012.
7. Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia. 1996;39:1546-1553.
8. Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand. 1997;160:413-422.
9. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101: 515-520.
10. Drucker DJ. Glucagon-like peptides. Diabetes. 1998;47:159-169.
11. Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96:737-745.
12. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;10:CD006423.
13. Byetta (exenatide) [package insert]. San Diego: Amylin Pharmaceuticals; 2009.
14. Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother. 2011;45:850-860.
15. Victoza (liraglutide) [package insert]. Princeton: Novo Nordisk; 2010.
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
17. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154:103-112.
18. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
19. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33:1509-1515.
20. Riddle M, Ahmann A, Basu A, Aroda V, Ratner R. Metformin+ exenatide+basal insulin vs metformin+placebo+basal insulin: reaching A1c, 6.5% without weight-gain or serious hypoglycemia. Diabetes. 2010;59(Suppl 1):Abstract 18-LB.
21. Morrow L, Hompesch M, Guthrie H, Chang D, Chatterjee DJ. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes Obes Metab. 2011;13:75-80.
22. Seino Y, Min K, Niemoller E, Takami A. Lixisenatide significantly improves glycemic control in Asian patients with T2DM insufficiently controlled on basal insulin +/- SU. Diabetes. 2011;60(Suppl 1):Abstract 278-OR.
23. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007; 357:1716-1730.
24. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408-416.
25. Apidra (insulin glulisine [rDNA origin] injection) [package insert]. Bridgewater: Sanofi-Aventis US; 2009.
26. Humalog (insuln lispro injection) [package insert]. Indianapolis: Lilly USA; 2011.
27. Novolog (insulin aspart [rDNA origin] injection) [package insert]. Princeton: Novo Nordisk; 2009.
28. Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167-177.
29. Mendoza CA, Mathew M, Chen J, et al. Exenatide promotes weight loss and improves insulin secretion, subclinical inflammation and hepatic steatosis when replaced for pre-meal insulin in T2DM patients. Diabetes. 2009;58(Supp 1):Abstract 507.
30. Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol. 2011;108:33B-41B.
31. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3: 153-165.